The TICI UNICO Launches Across European Markets
The first commercially available fully internal cochlear implant marks a transition from traditional behind-the-ear devices — which transfer sound from an external microphone and processor to an internal receiver — to full implants with the processor, microphone, and battery all under the skin,
reported a source. This milestone shifts neurotechnology into a fully subcutaneous design. Austrian manufacturer MED-EL rolled out the TICI UNICO across European markets in late September.
The device bypasses the standard behind-the-ear (BTE) peripherals that route signals externally. Instead, the TICI (totally implantable cochlear implant) integrates the processor, microphone, and power supply beneath the skin. According to Michael Cohen, MD, pediatric otolaryngologist at Mass Eye and Ear and associate professor at Harvard Medical School in Boston, cochlear implants have historically been viewed as “the first true neural implant.” He elaborated that decades of progress regarding biocompatibility, signal processing, and the interface between implants and neurons can guide broader applications in neural engineering.
Engineering Subcutaneous Microphones and Rechargeable Power Systems
Jennifer Robinson, MED-EL’s corporate director of product management hearing solutions, noted that developing a fully implantable cochlear implant required 50 years of work. She pointed to two “key” challenges: “developing an implanted microphone that can pick up sound through the skin” and “creating a rechargeable implanted battery.” Michael Daniele, PhD, professor of biomedical engineering at North Carolina State University in Raleigh, emphasized that integrating all necessary components into a tiny package represents a genuine engineering achievement.
Detecting and processing sound through the skin introduces unique engineering challenges. To solve power delivery, MED-EL paired the device with the GoPod, a wireless charging unit that magnetically aligns over the skin to replenish the internal cell. A full charge sustains operation for about 40 hours. The battery’s expected lifespan is roughly 15 years. If the subcutaneous power unit eventually fails, users retain the functional fallback of driving the system with a conventional BTE device.
Regulatory Pipelines and Clinical Trials Across the Global Market
While Europe sees the commercial rollout of MED-EL’s hardware, competing architectures move through regulatory channels. In the United States, Envoy Medical is advancing a device through the FDA’s premarket approval process. Envoy’s system uses a sensor designed to work with the ear’s natural structures rather than a microphone. Meanwhile, Cochlear, an Australian company, is testing its own candidate in clinical trials, recently reaching 1 million hours of testing in 100 patients.
These hardware iterations offer distinct operational advantages for specific patient demographics. Younger children frequently damage, lose, or put their BTE processor in their mouths. Subcutaneous placement removes those physical vectors of failure while simultaneously opening up usage scenarios for individuals with sensory sensitivities or those who spend extended periods near bodies of water. Alex Johnson, a longtime cochlear implant user based in Seattle, recalled wishing for a fully internal design during youth, though modern adult perspectives introduce nuanced technical and social reservations.
Navigating Stigmas, Revision Surgeries, and Patient Reactions
Patient communities have expressed mixed views on the concealment of neural hardware. Zachary Schwam, MD, neurotologist at Mount Sinai West and the Ear Institute at Mount Sinai in New York City, whose department performs 200 cochlear implant surgeries a year, observed that hidden processors attract many individuals seeking to sidestep the stigma associated with medical hardware. However, Johnson pointed out that focusing on the fact that you can’t see the device feels like erasure and may cater to making able-bodied people comfortable. Furthermore, removing visible hardware can complicate situations where users must communicate their deafness to others.
Surgical and financial hurdles also temper hardware enthusiasm. Clinical specialists advise against replacing BTE devices with an internal processor. Cohen warned that there is real risk with revision surgery, and whether there is a great enough advantage to warrant replacement remains unknown. Insurance also may not cover reimplantation if the current processor still works, Schwam said. Widespread adoption will ultimately depend on how the technology performs and how sound quality compares to current processors.
